BOSTON, May 15, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director.

In a recent transaction on August 8, Sangeeta N. Bhatia, a director at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), sold shares in the company, according to the latest SEC filings. The sale amounted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (NASDAQ: VRTX). Shares of the biotech ...

Vertex Securities Ltd Director Discussions: Check out the latest updates, and news about the Vertex Secur. director discussions at India Infoline Investor Relations ESG Profile ...

This was the stock's second consecutive day of losses.